February 7, 2014
Protease Inhibitors Make a First Splash
The first wave of new HCV drugs arrived in the form of two protease inhibitors, boceprevir (Victrelis) and telaprevir (Incivek), which were approved in the U.S. in 2011 for the treatment of HCV genotype 1. They have not yet been approved specifically for HIV-coinfected patients, however -- and Cox suggested that their day in the sun may be setting.
In clinical trials, boceprevir and telaprevir have both been shown to dramatically increase HCV treatment success rates in therapy-naive, HIV-coinfected patients. But they still must be taken with interferon, and both drugs have been found to exacerbate the adverse effects seen among patients taking interferon-based therapies. Between those sobering data and extensive drug-interaction concerns with HIV medications, "it's not easy to take these medications," Cox said.
Myles Helfand is the editorial director of TheBody.com and TheBodyPRO.com.
Follow Myles on Twitter: @MylesatTheBody.
|Inflammation Persists Despite Very Early HIV Treatment|
|Markers of Immune Exhaustion Predict Post-Treatment Control in HIV Patients|
|Ben Young: CROI 2015 Data Bolster the Call for Initiative to End HIV/AIDS Epidemic|
|New PrEP Results Exceed HIV Researchers' High Expectations|
|Coverage of CROI 2015: The 22nd Conference on Retroviruses and Opportunistic Infections|
|Women and PrEP: The Bridging Role of Local Health Departments|